Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company which develops and commercializes products in the therapeutic areas of allergy and respiratory disease. The Company's specialty pharmaceutical product candidates comprise pre-filled syringe for use in the emergency treatment of acute allergic reactions, and inhaler products for the treatment of bronchospasm, asthma and chronic obstructive pulmonary disease. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
14 (est)
Adamis Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

Key People/Management at Adamis Pharmaceuticals

Dennis J. Carlo

Dennis J. Carlo

CEO
Robert O. Hopkins

Robert O. Hopkins

CFO
Ronald Moss

Ronald Moss

CMO
Thomas Moll

Thomas Moll

VP of Research
David Marguglio

David Marguglio

SVP of Corporate Development

Adamis Pharmaceuticals Office Locations

Adamis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
11682 El Camino Real, Suite # 300
Show all (1)

Adamis Pharmaceuticals Financials and Metrics

Adamis Pharmaceuticals Financials

Adamis Pharmaceuticals's revenue was reported to be $6.5 m in FY, 2016
USD

Revenue (Q3, 2017)

3.4 m

Gross profit (Q3, 2017)

1.3 m

Gross profit margin (Q3, 2017), %

38%

EBIT (Q3, 2017)

(5.8 m)

Market capitalization (16-Feb-2018)

100.8 m

Cash (30-Sep-2017)

23.3 m
Adamis Pharmaceuticals's current market capitalization is $100.8 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

6.5 m

Cost of goods sold

4.9 m

Gross profit

1.6 m

Gross profit Margin, %

25%
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.9 m2.1 m3 m3.8 m3.4 m

Cost of goods sold

1.3 m1.8 m1.7 m1.9 m2.1 m

Gross profit

582.1 k254.5 k1.4 m1.9 m1.3 m

Gross profit Margin, %

30%12%45%51%38%
USDFY, 2014FY, 2015FY, 2016

Cash

5.4 m4.1 m4.1 m

Accounts Receivable

805.4 k

Inventories

14.5 k71 k942.1 k

Current Assets

4.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

119.6 k4.7 m2.1 m5.9 m11.2 m8.5 m6.3 m4.4 m417.1 k7.8 m399.5 k10.7 m23.3 m

Accounts Receivable

744.7 k595.6 k1.2 m1.2 m1 m

Inventories

1.2 m1.1 m914.2 k950 k996.1 k

Current Assets

2.2 m6 m11.3 m8.5 m6.4 m5 m2.6 m10.7 m26.5 m
    USDFY, 2014FY, 2015FY, 2016

    Depreciation and Amortization

    888.4 k2.5 m

    Inventories

    14.5 k(165 k)1.9 k

    Accounts Payable

    671 k116 k(1.7 m)

    Cash From Operating Activities

    5.4 m306 k
    USDQ1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Accounts Receivable

    744.7 k595.6 k1.2 m

    Inventories

    1.2 m914.2 k

    Accounts Payable

    547.7 k750 k977.2 k498 k408.8 k1.5 m4.2 m1.7 m2.7 m
      Y, 2017

      Financial Leverage

      1.2 x
      Show all financial metrics

      Adamis Pharmaceuticals Market Value History

      Adamis Pharmaceuticals's Web-traffic and Trends

      Adamis Pharmaceuticals Company Life and Culture

      You may also be interested in